Sutro Biopharma STRO

$ 2.52 -0.4%

Quarterly report 2024-Q3
added 11-13-2024

Sutro Biopharma Balance Sheet 2011-2024 | STRO

Annual Balance Sheet Sutro Biopharma

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-38.9 M	-13.6 M	-182 M	3.92 M	-111 M	-7.39 M	-11.6 M	-	-	-	-	-
Long Term Debt	-	3.77 M	15.7 M	24.5 M	8.88 M	10 M	-	-	-	-	-	-	-
Long Term Debt Current	6.42 M	4.58 M	1.04 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	55.2 M	118 M	110 M	-	-	-	-	-
Total Current Liabilities	93.7 M	66.5 M	41.7 M	29.6 M	33 M	36.4 M	-	-	-	-	-	-	-
Total Liabilities	321 M	190 M	88.8 M	62.1 M	58.6 M	91.6 M	150 M	160 M	-	-	-	-	-
Deferred Revenue	20.7 M	16.8 M	5.5 M	14.6 M	19.5 M	21.6 M	10.7 M	43.6 M	-	-	-	-	-
Retained Earnings	-559 M	-453 M	-333 M	-228 M	-196 M	-150 M	-115 M	-95.3 M	-	-	-	-	-
Total Assets	471 M	407 M	341 M	394 M	156 M	223 M	40.8 M	69.3 M	-	-	-	-	-
Cash and Cash Equivalents	69.3 M	47.3 M	30.4 M	206 M	4.96 M	125 M	22 M	-	-	-	-	-	-
Book Value	150 M	217 M	253 M	332 M	97.8 M	132 M	-109 M	-90.9 M	-	-	-	-	-
Total Shareholders Equity	150 M	217 M	253 M	332 M	97.8 M	132 M	-109 M	-90.9 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Sutro Biopharma

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	17.7 M	19.6 M	21.4 M	23.2 M	24.9 M	26.5 M	28.1 M	3.77 M	6.78 M	9.78 M	12.8 M	15.7 M	18.7 M	21.7 M	24.7 M	24.5 M	24.5 M	24.5 M	24.5 M	8.88 M	8.88 M	8.88 M	8.88 M	10 M	10 M	10 M	10 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	341 M	337 M	305 M	321 M	319 M	310 M	173 M	190 M	171 M	177 M	83.3 M	88.8 M	87.9 M	52.3 M	51.2 M	62.1 M	62.1 M	62.1 M	62.1 M	58.6 M	58.6 M	58.6 M	58.6 M	91.6 M	91.6 M	91.6 M	91.6 M	47.3 M	47.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	72.6 M	74 M	20.5 M	20.7 M	24 M	18 M	17.2 M	16.8 M	15.9 M	6.49 M	6.28 M	5.5 M	7.8 M	8.13 M	12.1 M	14.6 M	14.6 M	14.6 M	14.6 M	19.5 M	19.5 M	19.5 M	19.5 M	21.6 M	24.2 M	21.6 M	21.6 M	10.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-714 M	-666 M	-618 M	-559 M	-590 M	-541 M	-503 M	-453 M	-418 M	-399 M	-373 M	-333 M	-295 M	-264 M	-258 M	-228 M	-228 M	-228 M	-228 M	-196 M	-196 M	-196 M	-196 M	-150 M	-150 M	-150 M	-150 M	-115 M	-115 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	452 M	489 M	403 M	471 M	432 M	465 M	358 M	407 M	401 M	386 M	304 M	341 M	371 M	360 M	359 M	394 M	394 M	394 M	394 M	156 M	156 M	156 M	156 M	223 M	223 M	223 M	223 M	40.8 M	40.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	175 M	90.8 M	65.2 M	69.3 M	81.8 M	235 M	62.5 M	47.3 M	96.8 M	79.1 M	28.9 M	30.4 M	30.7 M	56.4 M	55.8 M	206 M	206 M	206 M	206 M	4.96 M	4.96 M	4.96 M	4.96 M	125 M	125 M	125 M	125 M	22 M	22 M	-	-	11.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	111 M	152 M	98 M	150 M	112 M	155 M	185 M	217 M	230 M	209 M	220 M	253 M	284 M	308 M	307 M	332 M	332 M	332 M	332 M	97.8 M	97.8 M	97.8 M	97.8 M	132 M	132 M	132 M	132 M	-6.5 M	-6.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	111 M	152 M	98 M	150 M	112 M	155 M	185 M	217 M	230 M	209 M	220 M	253 M	284 M	308 M	307 M	332 M	332 M	332 M	332 M	97.8 M	97.8 M	97.8 M	97.8 M	132 M	132 M	132 M	132 M	-109 M	-109 M	-	-	-90.9 M	-	-	-	-93.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency